PTEN and neoplasm: Moreover, PCa tumor cells frequently present PTEN loss (20% in primary tumors, 40% of mCRPC patients), which interacts with the interferon-1 (IFN-1) pathway, a pivotal step in the immune response, leading to its dysfunction and immunosuppression [20,21].